Compare Riot Platforms Inc (RIOT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Sanofi SA — how do they compare? Riot Platforms Inc trades at $16.89 (market cap $6.32B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 15.1× Riot Platforms Inc's market cap, and Sanofi SA pays a 6.01% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Riot Platforms Inc for 16 Days and Sanofi SA for 94 Days on average.
| RIOT | SNY | |
|---|---|---|
Market Cap | $6.32B | $95.18B |
Volume | 30,571,756 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $28.67 | $52.34 |
52-Week Low | $11.83 | $39.51 |
Typical Hold Time | 16 Days | 94 Days |
Enterprise Value | $6.73B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT stock trades at $16.84, down 9.17% in the past 24 hours amid bearish technical signals. The company shows concerning fundamentals with a net income margin of -196.28% and negative cash flow from operations of -$573 million in 2025. However, analyst sentiment remains overwhelmingly positive with 18 buy ratings and a consensus price target of $31.64, representing 88% upside potential. Recent strategic shifts toward AI data center operations with $9.8 billion in contracted lease revenue through 2048 provide long-term growth catalysts.
The outlook remains polarized between strong analyst optimism and challenging financial performance. Investment opportunity exists in RIOT's strategic pivot to AI infrastructure with secured long-term revenue streams, but substantial execution risks persist given current profitability challenges and negative cash flow generation. Stock investors face volatility from both Bitcoin price sensitivity and the company's transition to new business models.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
